APAC

A phase 2a open-label study to assess the safety, tolerability, and dosing regimen of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) in patients with peripheral arterial occlusive disease and chronic limb-threatening ischemia undergoing endovascular revascularization (HEALING -study)

Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia

A Phase II, randomized, blinded, dose selection study to assess safety and preliminary efficacy of antithrombotic heparin proteoglycan mimetic APAC (antiplatelet, anticoagulant) administered locally to the site of arterio-venous fistula (AVF) surgery to facilitate maturation of hemodialysis (HD) vascular access in patients with end stage kidney disease (ESKD) (MATURATION)